跳至主要内容
临床试验/NCT02532244
NCT02532244已完成不适用

Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases

Nemours Children's Clinic3 个研究点 分布在 1 个国家目标入组 230 人开始时间: 2015年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
230
试验地点
3
主要终点
genetic diagnosis

研究概览

简要总结

The goal of this study is to establish a genetic registry of patients with early-onset motor neuron and neuromuscular diseases. The investigators will collect samples from patients with a motor neuron or a neuromuscular disorder and their family members. The samples to be collected will be obtained using minimally invasive (whole blood) means. The research team will then extract high quality genomic DNA or RNA from these samples and use it to identify and confirm novel gene mutations and to identify genes which regulate the severity of motor neuron/neuromuscular diseases.

详细描述

Diseases affecting the motor unit--which is composed of the motor neuron, its myelin sheath and its innervated muscle fibers--are a diverse, heterogeneous group having heterogeneous clinical presentations and genetic causes. Many of these disorders have a inherited component. In some cases, the genetics underlying a given neuromuscular/motor neuron disease, like spinal muscular atrophy (SMA) or Duchenne muscular dystrophy, are well characterized. There are, however, disorders whose genetic basis has yet to be determined or genetically characterized diseases which harbor novel mutations. The purpose of this genetic registry is to catalogue early-onset motor neuron and neuromuscular disorders and to determine their genetic bases. With samples obtained from this registry, the investigators will be able to provide a genetic diagnosis for a specific neuromuscular/motor neuron disease which will lead to better care for those patients affected by these diseases.

Many of these disorders have a wide spectrum of phenotypic variability. For example, the severity of SMA is quite variable even though it is caused by the loss of a single gene, i.e. survival motor neuron 1 (SMN1). The number of copies of the duplicated gene survival motor neuron 2 (SMN2) dictates phenotypic severity in SMA. In this study, the research team will also identify potential modifiers of phenotypic severity for specific disorders like SMA and Charcot-Marie-Tooth (CMT) disease. With the identification of novel modifier genes, the investigators will be able to more accurately predict disease outcomes and the investigators will also have novel targets for the development of therapeutic agents for these diseases.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
1 Month 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of motor neuron/neuromuscular disease confirmed by neurologist
  • Be seen by one of the study investigators

排除标准

  • not seen by one of the study investigators

结局指标

主要结局

genetic diagnosis

时间窗: up to 2 years

The genetic basis for the subject's condition will be verified/determined by Sanger sequencing of DNA sample

次要结局

  • target gene protein levels(up to 2 years)
  • target gene mRNA levels(up to 2 years)
  • SMN2 copy number(up to 2 years)
  • SMN1 copy number(up to 2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Matthew E. R. Butchbach, Ph.D.

Research Scientist

Nemours Children's Clinic

研究点 (3)

Loading locations...

相似试验